Gilead, Novo team up to combine NASH compounds

A day after Gilead presented Phase II data at EASL for its cilofexor plus firsocostat combination to treat non-alcoholic steatohepatitis, the company partnered with Novo Nordisk to test the duo in combination with semaglutide in a clinical trial, totting up another combo partnership in the hot NASH field.

Dealmaking to create combinations has become a core component of pharmas’ strategies for NASH, because the consensus view is that no single therapy can control the multifactorial processes driving most patients’ disease (see "New Partners for NASH")...